In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 1, 1999, Pages 40-50

  Krecic Shepard, Mary Ellen ^a,b,c   Barnas, Crissy R ^a,b,c   Slimko, Jill ^a,b,c   Gorski, J Christopher ^a,b,c   Wainer, Irving W ^a,b,c   Schwartz, Janice B ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS GUAIFENESIN; DRUG METABOLITE; ERYTHROMYCIN; NORVERAPAMIL; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTITUSSIVE AGENTS; AREA UNDER CURVE; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; ERYTHROMYCIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; REFERENCE VALUES; VERAPAMIL;

EID: 0032797812     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70052-4     Document Type: Article

References (56)

1. 1. Wrighton S, Stevens J. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
2. 2. Watkins P. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-26.
3. 3. Shimada T, Yamazaki Hi Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals, studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
4. 4. Watkins P, Wrighton S, Schuetz E, Molowa D, Guzelian P. Identification of glucocorticoid-inducible cytochrome P450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
5. 5. De Waziers I, Cugnenc P, Yang C, Leroux JP, Beaune P. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol ExpTher 1990;252:387-94.
6. 6. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-97.
7. 7. Watkins P, Hamilton T, Annesley T, Ellis C, Kolars J, Voorhees J. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
8. 8. Ducharme J, Abdullah S, Wainer I. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr 1996;678: 113-28.
9. 9. Kovacs S, Martin D, Everitt D, Patterson S, Jorkasky D. Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998;63:617-22.
10. 10. May DG, Porter J, Wilkinson G, Branch R. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500.
11. 11. Kivisto K, Kroemer H. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37:40S-8S.
12. 12. Thummel K, Shen D, Podoll T, Kunze K, Trager W, Bacchi C, et al. Use of midazolam as a human cytochrome P450 3A probe; II: characterization of inter-and intra-individual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
13. 13. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
14. 14. Watkins P, Turgeon D, Saenger P, Lown K, Kolars J, Hamilton T, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450111A (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
15. 15. Kinirons M, O'Shea D, Downing T, Fitzwilliam A, Joellenbeck L, Groopman J, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
16. 16. Kolars J, Schmiedlin-Ren P, Schuetz J, Fang C, Watkins P. Identification of rifampin-inducible P450111A4 (CYP3A4)in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
17. 17. Kolars J, Awni W, Merion R, Watkins P. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
18. 18. Kolars J, Lown K, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton S, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
19. 19. Kroemer H, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992;260:1052-7.
20. 20. Kroemer H, Gautier J, Beaune P, Henderson C, Wolf C, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 1993;348:332-7.
21. 21. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995;353:116-21.
22. 22. Jones D, Gorski J, Hamman M, Hall S. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr 1996;678:105-11.
23. 23. Schwartz J. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990;255:364-73.
24. 24. Guengerich F, Turvy C. Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
25. 25. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
26. 26. von Molkte LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
27. 27. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre H, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46-58.
28. 28. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998;38:461-99.
29. 29. Madsen H, Nielsen KK, Brosen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995;39:433-9.
30. 30. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
31. 31. Lown K, Thummel K, Benedict P, Shen D, Turgeon D, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57: 16-24.
32. 32. Krivoruk Y, Kinirons M, Wood A, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-14.
33. 33. Glantz SA. Primer of biostatistics. 4th ed. New York: McGraw-Hill; 1997.
34. 34. Hunt C, Watkins P, Saenger P, Stave G, Barlascini N, Watlington C, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992;51:18-23.
35. 35. Rosenberg D. Dietary modulation of cytochrome P450 in the small intestinal epithelium. Pharmacology 1991;43: 36-46.
36. 36. Pantuck E, Pantuck C, Garland W, Min B, Wattenberg L, Anderson K, et al. Stimulatory effects of brussel sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25:88-95.
37. 37. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
38. 38. Schmider J, Greenblatt D, Fogelman S, Von Moltke L, Shader R. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997;18: 227-40.
39. 39. Wrighton S, Ring B, Watkins P, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:97-105.
40. 40. Lown K, Kolars J, Thummel K, Barnett J, Kunze K, Wrighton S, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
41. 41. Aoyama T, Yamano S, Waxman D, Lapenson D, Meyer U, Fischer V, et al. Cytochrome P450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989;264: 10388-95.
42. 42. Wu CY, Benet L, Hebert M, Gupta S, Rowland M, Gomez D, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
43. 43. Holtbecker N, Fromm M, Kroemer H, Ohnhaus E, Heidmann H. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-3.
44. 44. Olkkola K, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
45. 45. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-43.
46. 46. Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, Greenberg HE. Inhibition of hepatic and intestinal CYP3A4 by mibefradil measured by the erythromycin breath test (EBT) and oral midazolam pharmacokinetics (PK) [abstract]. Clin Pharmacol Ther 1999;65:131.
47. 47. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
48. 48. Stein W. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997;77:545-90.
49. 49. Sandstrom R, Karlsson A, Knutson L, Lennernas H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998;15:856-62.
50. 50. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters: a multivariate data analysis approach. J Med Chem 1998;41:4939-49.
51. 51. Schuetz EG, Yasuda K, Arimori K, Schuetz JD. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 1998;350:340-7.
52. 52. Hoflsi E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 1989;44:149-54.
53. 53. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, et al. Dextromethorphan (DM) N-demethylation (N-D) does not accurately reflect hepatic CYP3A phenotype. Clin Pharmacol Ther 1999; 65:170.
54. 54. Carrillo JA, Ramos SI, Agundez JA, Martinez C, Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998;20:319-24.
55. 55. Eichelbaum M, Somogyi A, von Unruh G, Dengler H. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol 1981;19:133-7.
56. 56. Schwartz J, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994;55:509-17.